# Randomized Phase I Study of Trimetrexate Glucuronate (TMTX) With Leucovorin (LCV) Protection Plus Dapsone Versus Trimethoprim / Sulfamethoxazole (TMP/SMX) for Treatment of Moderately Severe Episodes of Pneumocystis Carinii Pneumonia

> **NCT00002120** · PHASE1 · COMPLETED · sponsor: **U.S. Bioscience** · enrollment: 20 (—)

## Conditions studied

- Pneumonia, Pneumocystis Carinii
- HIV Infections

## Interventions

- **DRUG:** Trimetrexate glucuronate
- **DRUG:** Trimethoprim
- **DRUG:** Sulfamethoxazole
- **DRUG:** Dapsone
- **DRUG:** Leucovorin calcium

## Key facts

- **NCT ID:** NCT00002120
- **Lead sponsor:** U.S. Bioscience
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 20 (—)
- **Last updated:** 2005-06-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00002120

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00002120, "Randomized Phase I Study of Trimetrexate Glucuronate (TMTX) With Leucovorin (LCV) Protection Plus Dapsone Versus Trimethoprim / Sulfamethoxazole (TMP/SMX) for Treatment of Moderately Severe Episodes of Pneumocystis Carinii Pneumonia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00002120. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*